AMLX — Amylyx Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Amylyx Pharmaceuticals falls after US FDA withdraws approval for ALS drug
Amylyx to stop development of rare brain disorder drug after trial failure (updated)
Amylyx to stop development of rare brain disorder drug after trial failure
Amylyx Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Amylyx Pharma Q2 net loss wider than expected as R&D costs increase
Amylyx Pharmaceuticals Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis
Brief: Amylyx Pharmaceuticals Announces Positive Long-Term Results From Phase 2 Helios Clinical Trial Of Amx0035 In People With Wolfram Syndrome
Amylyx Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Amylyx Pharmaceuticals Q1 EPS USD -0.42 Vs. IBES Estimate USD -0.47
Amylyx Pharmaceuticals Inc expected to post a loss of 49 cents a share - Earnings Preview
Brief: Amylyx Pharmaceuticals Announces First Participant Dosed In Pivotal Phase 3 Lucidity Trial Of Avexitide In Post-Bariatric Hypoglycemia
Brief: Amylyx Pharma Announces First Participant Dosed In Phase 1, Multiple Ascending Dose Lumina Trial Of Amx0114 In People Living With Amyotrophic Lateral Sclerosis
U.S. STOCKS ON THE MOVE-Okta, Natgas companies, UnitedHealth
U.S. STOCKS ON THE MOVE-Capricor, Wave Life Sciences, EVgo
Amylyx Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Amylyx Pharmaceuticals falls on quarterly loss
Brief: Amylyx Pharmaceuticals Q4 EPS USD -0.55
Amylyx Pharmaceuticals Inc expected to post a loss of 52 cents a share - Earnings Preview